Wednesday September 23, 2020

HSE struggles to get fair price for cystic fibrosis treatment Orkambi

Manufacture Vertex has offered a reduced price but HSE negotiators believe it is too expensive

Susan Mitchell

Deputy Editor and Health Editor

30th October, 2016
Harris says Orkambi process not over yet. Picture: Fergal Phillips

The HSE is struggling to get what it regards as an acceptable price for the cystic fibrosis drug Orkambi.

Negotiations between the HSE and the drug’s manufacturer Vertex Pharmaceuticals have been going on for many weeks, with campaigners becoming increasingly frustrated by the lack of news.

While Vertex has offered a reduced price, HSE negotiators believe it remains too expensive. The HSE drugs committee is expected to meet to make a decision on...

Subscribe from just €1 for the first month!

Exclusive offers:

All Digital Access + eReader



Unlimited Access for 1 Month

Then €19.99 a month after the offer period.

Get basic
*New subscribers only
You can cancel any time.



€149 For the 1st Year

Unlimited Access for 1 Year

You can cancel any time.




90 Day Pass

You can cancel any time.

2 Yearly



Unlimited Access for 2 Years

This product does not auto-renew

Team Pass

Get a Business Account for you and your team

Share this post

Related Stories

'Even if we all go into lockdown, we're going to have twice as many cases in Dublin in two weeks, that's already seeded, the cheque's in the post' — Professor Tomás Ryan

Rachel Lavin | 1 day ago

A new road map for living with Covid-19 has taken the back seat to the surge of cases in the capital as coronavirus fatigue sets in – and one doctor warns ‘medicine doesn’t have all the answers’

Danielle Barron | 3 days ago

Comment: There is so little slack in our health service that tough decisions, even ones that reverse previous positions, will have to be taken

John Crown | 3 days ago